 patients with prostate cancer and other genitourinary malignancies.
Select trials that target the adenosine pathway
- Phase 2 trial of AZD4635 (A2A receptor antagonist) with durvalumab or with durvalumab and cabazitaxel for metastatic castration resistant prostate cancer (mCRPC) (AARDVARC) (NCT04495179)
- Phase 1/2 trial of etrumadenant (A2A and A2B receptor antagonist) plus zimberelimab (PD-1 antibody) combinations with or without standard of care treatments or etrumadenant plus AB680 (CD73 inhibitor) with or without zimberelimab for mCRPC (NCT04381832)
- Phase 1 trial of TTX-030 (CD39 inhibitor) with budigalimab (PD-1 inhibitor) with and without chemotherapy for solid tumors (including mCRPC and renal cell carcinoma) (NCT04306900)
- Phase 2 trial of AZD4635 (A2A receptor antagonist) with durvalumab, oleclumab (CD73 inhibitor) or both for mCRPC (NCT04089553)
- Phase 1/1b trial of NZV930 (anti-CD73 antibody) alone and in combination with PDR001 (PD-1 antibody) and/or NIR178 (A2A receptor antagonist) in advanced malignancies (including mCRPC and renal cell carcinoma) (NCT03549000)
- Phase 1 trial of CPI-006 (CD73 inhibitor) alone and in combination with ciforadenant (A2A receptor antagonist) and with pembrolizumab in advanced cancers (including mCRPC, bladder cancer and renal cell carcinoma) (NCT03454451)
- Phase 2 trial of NIR178 (A2A receptor antagonist) in combination with PDR001 (PD-1 antibody) in non-hodgkins lymphoma and solid tumors (including mCRPC, urothelial carcinoma and renal cell carcinoma) (NCT03207867)
- Phase 1/1b trial of ciforadenant (A2A receptor antagonist) alone and in combination with atezolizumab in advanced cancers (including mCRPC and renal cell carcinoma) (NCT02655822)
- Knowles JR. "Enzyme-catalyzed phosphoryl transfer reactions." Annu Rev Biochem 1980; 49:877-919.
- Mishra N, Tuteja R, Tuteja N. "Signaling through MAP kinase networks in plants." Arch Biochem Biophys 2006; 452:55-68.
- Di Virgilio, et al. "Extracellular ATP and P2 purinergic signalling in the tumour microenvironment." Nat Rev Cancer 2018; 18:601-18.
- Spychala J. "Tumor-promoting functions of adenosine." Pharmacol Ther 2000; 87:161-73.
- Blay J, White TD, Hoskin DW. "The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine." Cancer Res 1997; 57:2602-5.
- Hasko G, Linden J, Cronstein B, Pacher P. "Adenosine receptors: therapeutic aspects for inflammatory and immune diseases." Nat Rev Drug Discov 2008; 7:759-70.
- Ohta A, et al. "A2A adenosine receptor protects tumors from antitumor T cells." Proc Natl Acad Sci USA 2006; 103:13132-7.
- Kantoff PW, et al. "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer." N Engl J Med 2010; 363:411-22.
- Kwon ED, et al. "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial." Lancet Oncol 2014; 15:700-12.
- Beer TM, et al. "Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer." J Clin Oncol 2017; 35:40-7.
- Antonarakis EA, et al. "Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study." J Clin Oncol 2020; 38:395-405.
- Sweeney CJ, et al. "Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study."Cancer Res 2020 (80) (16 Suppl) CT014.
- Kirschenbaum A, et al. "The Association Between Psychiatric Disorders and Telomere Length: A Meta-Analysis Involving 14,827 Persons." Ann NY Acad Sci 2011; 123:64-70.
- Xu H, et al. "Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP?." Dis Markers 2019; 7090545.
- Vecchio EA, et al. "Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell